Join Oryzon Genomics for a data call to discuss topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disorder (BPD).

Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor in PhIIb in BPD and schizophrenia. PORTICO (EudraCT No.: 2020-003469-20, ClinicalTrials.gov Identifier NCT04932291) is a global double-blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial evaluating the efficacy and safety of vafidemstat in a BPD population. The study recruited a total of 210 patients, randomized 1:1 in two arms, across 27 sites in the US and Europe. The trial had two independent primary endpoints: reduction of agitation and aggression and overall disease improvement in BPD severity.

A live question and answer session will follow the formal presentations.